NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease

Course Provider
National Comprehensive Cancer Network
Learning Objectives
Participants will describe the rationale for the use of bispecific T-cell antibodies in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Participants will review the safety and efficacy data from clinical trials that have evaluated bispecific T-cell antibodies in patients with relapsed/refractory DLBCL.
Participants will identify the adverse events of special interest (AESI) associated with bispecific T-cell antibodies and develop an appropriate supportive care intervention for the management of AESI.
Course Offering: Meeting, Seminar, Workshop, or Webinar - Live (delivered in real time)
Domain Focus: Psychosocial Concepts and Support Systems
Start Date:
End Date:
CE Credits: 1.00
Fee: $0.00
Learn More